Chickenpox Market

 Market Overview:

The 7 major chickenpox markets are expected to exhibit a CAGR of 3.9% during 2024-2034.

The chickenpox market has been comprehensively analyzed in IMARC's new report titled "Chickenpox Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chickenpox, also known as varicella, refers to a highly contagious viral infection induced by the varicella-zoster virus (VZV). It is characterized by an itchy rash that usually starts on the face, chest, and back and then spreads to other parts of the body. The rash develops from red bumps to fluid-filled blisters, which eventually crust over and form scabs. Numerous other symptoms may include fever, headache, fatigue, sore throat, loss of appetite, swollen lymph nodes, etc. The disease usually spreads through respiratory droplets or direct contact with the fluid from the lesions of an infected person. The diagnosis of chickenpox is primarily based on clinical presentation, medical history, and laboratory tests. A healthcare provider will examine the skin to look for characteristic signs of the ailment, including a rash. In addition to this, a direct fluorescent antibody test is also utilized, which involves staining a sample taken from a skin lesion or blister with a fluorescent dye to detect the presence of the virus among individuals suffering from this condition.

The increasing incidence of viral diseases, which can spread through airborne transmission when an infected person coughs or sneezes, is primarily driving the chickenpox market. In addition to this, the rising prevalence of congenital or acquired immunodeficiency disorders that can impair the body's ability to fight off pathogens is creating a positive outlook for the market. Moreover, the widespread adoption of over-the-counter pain relievers, such as acetaminophen, naproxen, ibuprofen, etc., to reduce fever, ease discomfort, and improve the quality of life is also bolstering the market growth. Apart from this, the inflating utilization of topical calamine lotion, since it works by producing a cooling sensation and forming a protective barrier that shields the blisters from further irritation, friction, and scratching, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of silicone gel sheets or dressings for the treatment of severe disease conditions on account of their numerous advantages, like enhanced synthesis of collagen, retained moisture, improved appearance of scars over time, etc., is expected to drive the chickenpox market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the chickenpox market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chickenpox and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chickenpox market in any manner.

Key Highlights:

• Chickenpox is mostly a pediatric disease, with more than 90% of cases involving children under the age of ten.
• The most susceptible age group to chickenpox was 6-10 years old (27.74%), followed by 1-5 years old (17.08%) and 11-15 years old (15.74%).
• The majority of cases (97.26%) had mild-to-moderate symptoms and did not require hospitalization.
• Chickenpox is rare in the United States, with less than 150,000 cases, 1,400 hospitalizations, and 30 deaths each year.
• Adult chickenpox is more common in tropical and semitropical regions than in temperate areas (for example, the United States and Europe).

Drugs:

VALTREX is approved for the management of chickenpox in immunocompetent pediatric persons aged 2 to less than 18 years. Based on efficacy results from clinical studies with oral acyclovir, treatment with VALTREX should be started within 24 hours after the development of the rash.

ZOVIRAX is the brand name for acyclovir, which is a synthetic nucleoside analogue that works against chickenpox. ZOVIRAX capsules, tablets, and suspension are for oral administration. Each ZOVIRAX capsule includes 200 mg of acyclovir and the inert components of maize starch, lactose, magnesium stearate, and sodium lauryl sulfate. The capsule shell contains gelatin, FD&C Blue No. 2, and titanium dioxide.

CRV-101 refers to an under-development vaccine candidate designed to provide immunity against the varicella-zoster virus, which causes chickenpox. Such vaccines are developed through comprehensive clinical trials to confirm their safety, efficacy, and immunogenicity before being approved by regulatory agencies, including the FDA in the United States.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chickenpox market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chickenpox market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chickenpox marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chickenpox market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chickenpox market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chickenpox market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chickenpox across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chickenpox by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chickenpox by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with chickenpox across the seven major markets?
• What is the size of the chickenpox patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chickenpox?
• What will be the growth rate of patients across the seven major markets?
   

Chickenpox: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chickenpox drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chickenpox market?
• What are the key regulatory events related to the chickenpox market?
• What is the structure of clinical trial landscape by status related to the chickenpox market?
• What is the structure of clinical trial landscape by phase related to the chickenpox market?
• What is the structure of clinical trial landscape by route of administration related to the chickenpox market?